Logo image of TBIO

TELESIS BIO INC (TBIO) Stock Fundamental Analysis

USA - NASDAQ:TBIO - US1920032000 - Common Stock

3.23 USD
-0.76 (-19.05%)
Last: 9/27/2024, 8:22:41 PM
2.85 USD
-0.38 (-11.76%)
After Hours: 9/27/2024, 8:22:41 PM
Fundamental Rating

1

Taking everything into account, TBIO scores 1 out of 10 in our fundamental rating. TBIO was compared to 56 industry peers in the Life Sciences Tools & Services industry. TBIO has a bad profitability rating. Also its financial health evaluation is rather negative. TBIO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TBIO has reported negative net income.
TBIO had a negative operating cash flow in the past year.
In the past 5 years TBIO always reported negative net income.
In the past 5 years TBIO always reported negative operating cash flow.
TBIO Yearly Net Income VS EBIT VS OCF VS FCFTBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

TBIO has a worse Return On Assets (-98.37%) than 92.98% of its industry peers.
TBIO has a worse Return On Equity (-521.49%) than 91.23% of its industry peers.
Industry RankSector Rank
ROA -98.37%
ROE -521.49%
ROIC N/A
ROA(3y)-54.24%
ROA(5y)-50.23%
ROE(3y)-104.32%
ROE(5y)-94.65%
ROIC(3y)N/A
ROIC(5y)N/A
TBIO Yearly ROA, ROE, ROICTBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

With a Gross Margin value of 47.88%, TBIO perfoms like the industry average, outperforming 54.39% of the companies in the same industry.
TBIO's Gross Margin has improved in the last couple of years.
TBIO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 47.88%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.78%
GM growth 5YN/A
TBIO Yearly Profit, Operating, Gross MarginsTBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 -100 -200 -300

More info and screens

2

2. Health

2.1 Basic Checks

TBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TBIO has been increased compared to 1 year ago.
TBIO has a better debt/assets ratio than last year.
TBIO Yearly Shares OutstandingTBIO Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 500K 1M 1.5M
TBIO Yearly Total Debt VS Total AssetsTBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

TBIO has an Altman-Z score of -6.48. This is a bad value and indicates that TBIO is not financially healthy and even has some risk of bankruptcy.
TBIO's Altman-Z score of -6.48 is on the low side compared to the rest of the industry. TBIO is outperformed by 91.23% of its industry peers.
A Debt/Equity ratio of 0.54 indicates that TBIO is somewhat dependend on debt financing.
TBIO has a worse Debt to Equity ratio (0.54) than 63.16% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.54
Debt/FCF N/A
Altman-Z -6.48
ROIC/WACCN/A
WACC14.42%
TBIO Yearly LT Debt VS Equity VS FCFTBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

A Current Ratio of 1.89 indicates that TBIO should not have too much problems paying its short term obligations.
TBIO has a worse Current ratio (1.89) than 61.40% of its industry peers.
TBIO has a Quick Ratio of 1.72. This is a normal value and indicates that TBIO is financially healthy and should not expect problems in meeting its short term obligations.
TBIO's Quick ratio of 1.72 is in line compared to the rest of the industry. TBIO outperforms 45.61% of its industry peers.
Industry RankSector Rank
Current Ratio 1.89
Quick Ratio 1.72
TBIO Yearly Current Assets VS Current LiabilitesTBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

2

3. Growth

3.1 Past

TBIO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1673.33%.
Looking at the last year, TBIO shows a very negative growth in Revenue. The Revenue has decreased by -43.65% in the last year.
TBIO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 61.13% yearly.
EPS 1Y (TTM)-1673.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2621.43%
Revenue 1Y (TTM)-43.65%
Revenue growth 3Y61.13%
Revenue growth 5YN/A
Sales Q2Q%-82.09%

3.2 Future

TBIO is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -29.72% yearly.
TBIO is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -40.92% yearly.
EPS Next Y-122.26%
EPS Next 2Y-29.72%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-66.55%
Revenue Next 2Y-40.92%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
TBIO Yearly Revenue VS EstimatesTBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
TBIO Yearly EPS VS EstimatesTBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TBIO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TBIO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TBIO Price Earnings VS Forward Price EarningsTBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TBIO Per share dataTBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20

4.3 Compensation for Growth

A cheap valuation may be justified as TBIO's earnings are expected to decrease with -29.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-29.72%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

TBIO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TELESIS BIO INC

NASDAQ:TBIO (9/27/2024, 8:22:41 PM)

After market: 2.85 -0.38 (-11.76%)

3.23

-0.76 (-19.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-07 2024-08-07/amc
Earnings (Next)11-11 2024-11-11/amc
Inst Owners2.63%
Inst Owner Change0%
Ins Owners5195.21%
Ins Owner Change0%
Market Cap5.72M
Analysts82.86
Price Target4.08 (26.32%)
Short Float %0.03%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-58.05%
Min EPS beat(2)-85.37%
Max EPS beat(2)-30.72%
EPS beat(4)0
Avg EPS beat(4)-35.22%
Min EPS beat(4)-85.37%
Max EPS beat(4)-2.5%
EPS beat(8)4
Avg EPS beat(8)-9.5%
EPS beat(12)5
Avg EPS beat(12)-9.14%
EPS beat(16)8
Avg EPS beat(16)19.54%
Revenue beat(2)0
Avg Revenue beat(2)-63.87%
Min Revenue beat(2)-76.62%
Max Revenue beat(2)-51.12%
Revenue beat(4)0
Avg Revenue beat(4)-39.08%
Min Revenue beat(4)-76.62%
Max Revenue beat(4)-2.28%
Revenue beat(8)2
Avg Revenue beat(8)-15.2%
Revenue beat(12)4
Avg Revenue beat(12)-9.56%
Revenue beat(16)5
Avg Revenue beat(16)-24.1%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-101.22%
EPS NY rev (1m)0%
EPS NY rev (3m)-64.47%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-74.68%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-65.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.33
P/FCF N/A
P/OCF N/A
P/B 0.57
P/tB 1
EV/EBITDA N/A
EPS(TTM)-23.94
EYN/A
EPS(NY)-19.27
Fwd EYN/A
FCF(TTM)-12.84
FCFYN/A
OCF(TTM)-12.31
OCFYN/A
SpS9.9
BVpS5.62
TBVpS3.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -98.37%
ROE -521.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 47.88%
FCFM N/A
ROA(3y)-54.24%
ROA(5y)-50.23%
ROE(3y)-104.32%
ROE(5y)-94.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.78%
GM growth 5YN/A
F-Score4
Asset Turnover0.33
Health
Industry RankSector Rank
Debt/Equity 0.54
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 40.13%
Cap/Sales 5.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.89
Quick Ratio 1.72
Altman-Z -6.48
F-Score4
WACC14.42%
ROIC/WACCN/A
Cap/Depr(3y)185.64%
Cap/Depr(5y)117.94%
Cap/Sales(3y)13.42%
Cap/Sales(5y)9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1673.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2621.43%
EPS Next Y-122.26%
EPS Next 2Y-29.72%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-43.65%
Revenue growth 3Y61.13%
Revenue growth 5YN/A
Sales Q2Q%-82.09%
Revenue Next Year-66.55%
Revenue Next 2Y-40.92%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y7.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year49.86%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y52.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.42%
OCF growth 3YN/A
OCF growth 5YN/A